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Abstract
Background: BK and JC polyomaviruses (BKV and JCV) are potentially oncogenic and have in the past inconclusively been
associated with tumours of the central nervous system (CNS), while BKV has been hinted, but not confirmed to be
associated with neuroblastomas. Recently three new polyomaviruses (KIPyV, WUPyV and MCPyV) were identified in humans.
So far KIPyV and WUPyV have not been associated to human diseases, while MCPyV was discovered in Merkel Cell
carcinomas and may have neuroepithelial cell tropism. However, all three viruses can be potentially oncogenic and this
compelled us to investigate for their presence in childhood CNS and neuroblastomas.
Methodology: The presence of KI, WU and MCPyV DNA was analysed, by a joint WU and KI specific PCR (covering part of
VP1) and by a MCPyV specific regular and real time quantitative PCR (covering part of Large T) in 25 CNS tumour biopsies
and 31 neuroblastoma biopsies from the Karolinska University Hospital, Sweden. None of the three new human
polyomaviruses were found to be associated with any of the tumours, despite the presence of PCR amplifiable DNA assayed
by a S14 housekeeping gene PCR.
Conclusion: In this pilot study, the presence of MCPyV, KI and WU was not observed in childhood CNS tumours and
neuroblastomas. Nonetheless, we suggest that additional data are warranted in tumours of the central and peripheral
nervous systems and we do not exclude that other still not yet detected polyomaviruses could be present in these tumours.
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Introduction
Polyomaviruses are DNA tumour viruses that were first
described in humans with the simultaneous discovery of JC virus
(JCV) and BK virus (BKV) in 1971 [1,2]. JCV has a unique
tropism for replication in glial cells and its replication in humans
can cause progressive multifocal leucoencephalopathy (PML), a
fatal demyelinating disease of the central nervous system (CNS) in
immunosuppressed patients [2,3]. During three decades of
research, JCV has been shown to transform cells in culture,
particularly cells of glial origin and to have a highly oncogenic
potential in laboratory animals (reviewed in [4]). Moreover, in
humans, JCV has been associated with CNS tumours [5,6], but so
far, the data are inconclusive to pinpoint such an association
[7,8,9,10,11]. BKV is associated with nephropathy and hemor-
rhagic cystitis in renal and allogeneic haematopoietic stem cell
transplant recipients, respectively (reviewed in [3]). In newborn
rodents, BKV is also highly oncogenic, and although it can be
found in experimental tumours of the CNS its association to the
nervous system is assumed to be weaker than that of JCV
[3,12,13]. Moreover, a possible role for BKV in the aetiology of
embryonal neuroblastomas of the sympathetic nervous system has
been suggested [14] but also disputed [15] and similarly studies on
BKV in human brain tumours present conflicting and inconclusive
results (reviewed in [16]).
Recently, three new polyomaviruses, KI, WU and MC
polyomaviruses [17,18,19] have been identified in humans. These
three viruses are, with regard to protein sequences, rather different
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and MCPyV diverging from all earlier human polyomaviruses
[20].
To date, KI and WU polyomaviruses (KIPyV and WUPyV)
have not been associated to human diseases. Although many
reports have confirmed their discovery in nasopharyngeal aspirates
from patients suffering from acute respiratory diseases, so far the
data do not suggest that KIPyV and WUPyV are aetiological
agents for acute respiratory diseases [3,21,22,23] and there is still
limited information regarding the tropism of KIPyV and WUPyV
[20]. Nevertheless, as members of the polyomavirus family,
KIPyV and WUPyV have all the qualifications to be cofactors
in the induction and/or progression of human tumours.
With the discovery of MCPyV in 2008, for the first time a
strong association between a human cancer and a polyomavirus
was demonstrated and later confirmed by several groups (reviewed
in [3]). The presence of MCPyV in Merkel cell carcinomas
(MCC), its integration [19,24] and its clonal mutation in the C-
terminal region of the Large T antigen [25], merit further
investigation both on the epidemiological and in vitro level in order
to conclude in a direct oncogenic role of this polyomavirus
according to the criteria of Harald zur Hauzen (detailed in [16]).
There is limited information regarding the tropism of MCPyV,
which can also be found in nasopharyngeal aspirates
[26,27,28,29], nonetheless the discovery in Merkel cell carcinomas
indicates a tropism for neuroepithelial cells. Several studies have
been conducted to investigate for the presence of MCPyV in other
human tumours. So far MCC is the only tumour type where
MCPyV has been shown to be present and integrated in the
cellular genome, suggesting a causative role in the cancer
development. Notably, MCPyV DNA has not been demonstrated
in non-UV [30] or UV-light exposed melanomas [31,32,33,34], in
prostate cancer [35], in lymphoid tissues and tumours [36], in
neuroendocrine tumours of the skin, in pulmonary neuroendo-
crine carcinomas [37], or in a diversity of human tumours
including 21 neuroblastomas [24,38], all from small children
(Xavier Sastre-Garau personal communication). Hence, so far
none of these studies suggests an aetiological role of MCPyV in
any of these tumours. Nevertheless, to our knowledge, no study has
been conducted regarding the presence of MCPyV in tumours of
the central nervous system.
It is not unlikely that a virus, and particularly a polyomavirus is
a causative agent of a tumour that arises early in life [39,40].
Furthermore, very recently, a report was published describing the
presence of WUPyV and KIPyV DNA in CNS tissue from HIV
positive, but not from HIV negative, individuals [41]. Nonetheless,
in a separate study, MCPyV DNA was not found in the
cerebrospinal fluid from HIV positive men [42].
The data reviewed above compelled us to investigate for the
presence of KI, WU and MC polyomaviruses in childhood
tumours more specifically CNS tumours and neuroblastomas.
CNS tumours are the most common solid tumours in children
and account for 27% of all childhood malignancies, second only to
leukaemias [43,44]. The predominant types of CNS tumours in
children are astrocytomas, medulloblastomas/PNET, brainstem
gliomas and ependymomas [44]. Neuroblastoma represents 5.5%
of all childhood malignancies and is one of the most common extra
cranial solid tumours in childhood [43]. The majority of these
tumours are of embryonal origin and affects children at a very
young age, with a median age at 18 months, being the most
common malignancy in infants [45]. Neuroblastomas are derived
from the neural crest cells and develops in tissues along the
sympathetic nervous system, most frequently in the adrenal glands,
or elsewhere in the abdomen, chest, neck and pelvis [46].
Here,in a pilot study we reportthe firstanalysis for presenceofKI,
WU and MCPyV DNA in tumour samples of 25 consecutive patients
diagnosed during2008–2009withCNS tumoursand 30patientswith
neuroblastomas diagnosed between 1991 and 2008 at the Karolinska
University Hospital. In addition, sera from 18/25 patients with CNS
tumours were analysed for antibody titres against MCPyV.
Materials and Methods
Ethic Statements
For all patients in this study, written informed consent was
obtained. This study was approved by the Regional Ethical
Committee of Stockholm, Sweden.
Patients, Tumour Material and Sera
Twenty-five fresh frozen CNS tumours from patients aged 0 to
18 years old were collected prospectively at the Astrid Lindgrens
Children’s Hospital within the Karolinska University Hospital
between March 2008 and September 2009. In the operation room
a biopsy measuring in average 262 mm could be collected from
each tumour (a larger material was sometimes available).
Additionally, in 14 cases, pieces from the ultrasound aspirate
could be obtained at the end of the operation. For 18/25 patients
blood samples could be collected at the operation room, or within
1 week after operation and stored 220uC. Patients and CNS
tumours characteristics are detailed in Table 1 and grouped
according to the Birch and Marsden classification scheme [47] in
Table 2. In addition, 31 fresh frozen neuroblastomas from 30
patients, 0 to 11.5 years old, were collected prospectively between
1991 and 2008. More specifically, one patient had two biopsies
from separate manifestations of multifocal disease [48]. The
sample size of the neuroblastomas was considerably larger and
allowed us to extract sufficient amount of DNA from each tumour.
DNA Extraction from Fresh Frozen Samples
The QIAamp DNA Mini Kit 50 (QIAgenH) (QIAGEN AB,
Solna, Sweden) for blood and tissues was used according to the
manufacturer’s protocol to perform the extraction.
Verification of Amplifiable DNA
To avoid false negative results due to DNA unsuitable for PCR
analysis, a control PCR with human ribosomal gene S14 primers
[49,50] was run with 100–120 ng DNA for all samples.
PCR Assay for the Detection of KIPyV and WUPyV
To detect KIPyV or WUPyV simultaneously, a standard PCR
described previously [30] was used with a single primer pair
hybridizing to a conserved genomic region shared by KIPyV and
WUPyV in the gene encoding the capsid protein VP1,
KIPyV2263F (59-TTGGATGAAAATGGCATTGG-39) and KI-
PyV2404R (59-TAACCCTTCTTTGTCTAAAATGTAGCC-
39). The KIPyV2404R primer has an A/G mismatch with
published WUPyV sequences at base number 20 (underlined).
The resulting amplicon was 142 bp. The reaction mix was added
to 100 ng of template DNA. As a positive control, KIPyV bp
1493–2653 was cloned into pcDNA3 [30].
PCR Assay for the Detection of MCPyV
To detect the presence of MCPyV DNA, a standard PCR
described previously [30] was used with a single primer pair
hybridizing the N-terminal part of the LT region of MCPyV,
MCPyLT1709.F (59-CAGGCATGCCTGTGAATTAGGATG-39)
and MCPyVLT1846.R (59-TCAGGCATCTTATTCACTCC-39).
Polyomavirus in Human Tumours
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reaction mix was added to 100 ng of template DNA. The resulting
amplicon was 138 bp.
Real-Time PCR Assay for the Detection of MCPyV
A hydrolysis probe–based, real-time PCR (rtPCR) designed to
target the large T antigen (LT) gene, described previously, was used
[26]. Reactions were performed with 100 ng of template DNA.
MCPyV Serology Measured by a Neutralization Assay
A neutralization assay described previously [51] was used for
detection of anti MCPyV antibodies. Titres were calculated using
Prism software (GraphPad) from sigmoidal curves of four-fold
serial dilutions of the sera.
Results and Discussion
In this study, we have searched for a possible association of KI,
WU or MC polyomaviruses with development of childhood
tumours of the neural systems by investigating 25 CNS tumours
and 31 neuroblastomas.
The presence of amplifiable DNA by a control PCR with
human ribosomal gene S14 primers was confirmed in all tested
samples, while DNA from KI, WU or MCPyV was not detected
by regular PCR in any of the biopsies from the 25 CNS tumours,
Table 1. Characteristics of patients and their CNS tumours.
Patient
Gender/
Age
1 Localisation Other diagnosis
Volume
High6Length6Width
(mm) Histopathology (WHO)
1 F/5 Chiasma opticum 39628626 Pilomyxoid astrocytoma grade II
2 F/3 Intramedullary (C6-T9) 90615617 Ganglioglioma grade I
3 M/4/18* 4
th Ventricle 22620626
2 Ependymoma grade III
4 M/8/11 Front of 3
rd Ventricle,
next to foramen Monroi
Neurofibromatosis type I,
malignant optic nerve glioma
15620614 Pilocytic astrocytoma grade I
5 F/10 Bilateral subependymal,
next to foramen Monroi
Tuberous sclerosis 28628645
2 Subependymal giant cell
astrocytoma grade I
6 M/1 Posterior fossa 50640656 Teratoid/rhabdoid tumour grade IV
7 F/4/13 Intramedullary (L2-L3) Neurofibromatosis type II,
meningioma, Bilateral acoustic
neuroma
30615619 Schwannoma grade I
(MIB index 10–12%)
8 M/1 Subependymal, next to
foramen Monroi
Tuberous sclerosis 17620614 Giant cell strocytoma grade I
9 F/9 Left frontal, from chiasma
to corner of side ventricle
39628637 Atypic neurocytoma grade II
10 M/6 4
th Ventricle 29623626 Metastatic medulloblastoma
grade IV, classic variant
11 M/5 Cerebellum 63657653 Pilocytic astrocytoma grade I
12 M/2/11 Back side of left frontal
lobe and medullar
Leptomeningeal
oligodendromatosis
15610616 Oligodendroglioma
13 M/6 Posterior fossa 23619618 Ependymoma grade III
14 M/0/2 Left subependymal,
next to foramen Monroi
Tuberous sclerosis 9614612 Subependymal giant cell
astrocytoma grade I
15 M/5 Pons 32632630 Pilocytic ponsglioma grade I
16 M/4 Frontoparietal right 26627622 Dysendrioblastic neuroepithelial tumour
17 F/4/8* 3
rd Ventricle and hypothalamus 31633621 Pilocytic astrocytoma grade I
18 M/3 Posterior fossa 30635640 Metastatic medulloblastoma
grade IV, classic variant
19 M/8/11* Posterior fossa 30637631 Pilocytic astrocytoma grade I
20 M/15 Left frontal supratentorial 57652685 Anaplastic oligoastrocytoma with undifferenciated
component grade III-IV or small cell glioblastoma
with undifferenciated component grade IV
21 M/14 Posterior fossa and
4
th ventricle
29619621 Metastatic Medulloblastoma
grade IV, classic variant
22 F/2 Left frontal lobe 52649641 Supratentorial primitive
neuroectodermal tumour (PNET) grade IV
23 M/5/12* Intramedullary (C0-C6) 5069612 Cervicospinal astrocytoma grade I
24 M/3 Intramedullary (T5-T7) 50670650 Ependymoma grade II
25 M/0 Frontal bilateral 45660680 Desmoplastic Infantil tumour
1Age at diagnosis/age at operation (* relapsing tumour).
2Multiple nodules.
doi:10.1371/journal.pone.0008239.t001
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the 31 neuroblastomas (Table 3). Furthermore, for a better
sensitivity, we complemented our standard MCPyV PCR with a
real-time PCR for MCPyV. All our samples remained MCPyV
DNA negative in this PCR with one exception: a sample with a
Ct value of 37.8. It was derived from an ultrasound aspirate,
while the corresponding biopsy directly taken from the tumour in
the brain was negative in the same PCR. Thus, the presence of
MCPyV in the tumour cells could not be confirmed. Conse-
quently, we concluded that none of the tested CNS or
neuroblastoma tumour samples scored positive for any of the
three tested viruses.
In addition, we tested sera available from 18/25 CNS tumour
patients for MCPyV-specific antibody responses (Table 4). Of
the tested sera 56% were completely negative in a highly
sensitive neutralization assay, which very accurately excludes
false negative results and has been described previously [51]. Of
the MCPyV antibody-positive sera, all but one had antibody
titres within two fold of the geometric mean titre (2700)
calculated from an adult population (between 47 and 75 years
old) tested earlier [51]. The remaining patient had an antibody
titre of 98,740, which, while greater than the titres of other
subjects in this study, was still below the geometric mean titre
(160,000) reported for patients suffering from MCPyV-associated
Merkel cell carcinomas [51].
In all the PCR-based assays all samples contained 100 ng
of DNA equal to the DNA content of .16 000 cells. The
methods used for detection of KI, WU and MC polyomaviruses,
were highly sensitive and should be adequate for the detection of
low quantities of virus DNA reaching the detection level of 0.1
virus/copy per cell or less. The PCR used for the simultaneous
detection of the related KI and WU polyomaviruses is known
to detect as few as 10 copies of a KIPyV VP1 gene containing
plasmid [30] corresponding to a detection limit of ,0.001 viral
DNA copies/cell genome. For detection of MCPyV we
performed a previously established PCR assay using primers
situated outside of the helicase domain and generating an
amplicon of 138 bp [30]. With this assay, 1000 copies of a
plasmid, pUC57MC1, containing the corresponding region of
LT could be detected corresponding to a detection limit of ,0.1
viral DNA copies/cell genome. To confirm that the detection
limits of these two assays were unaffected by the presence of
cellular DNA, up to 1000 ng of genomic DNA was mixed with
plasmid DNA containing viral sequences without any reduction
in the sensitivity (data not shown). In addition, we also used a
previously established real time quantitative PCR for MCPyV
[26], where a plasmid control with 2 copies/reaction was
reproducibly positive, corresponding to ,0.0002 copies/cell
genome. Lastly, all tumour biopsies were fresh frozen and
demonstrated amplifiable DNA in a PCR using human ribosomal
gene S14 primers and resulting in 150 bp amplimers.
To our knowledge this is the first time the presence of the
three newly discovered polyomavirus has been investigated in
childhood CNS tumours and so far the results are negative,
indicating that MCPyV, KI and WU polyomaviruses do not play
a major, persistent role in oncogenesis of childhood CNS
tumours. The data should however be taken with caution, since
our analysis includes a limited number of CNS tumours of
several diagnostic subsets, although the proportion of each
tumour group was fairly similar to that of the Swedish registry
(Table 2). Furthermore it should be noted that 6/25 (24%)
patients had a genetic cancer syndrome known to play a role for
CNS tumour development (Table 1), a proportion above the
average population.
The absence of MCPyV in neuroblastomas here supports the
similar negative finding in the 21 neuroblastomas of Sastre-Garau
et al. [24] and suggests that MCPyV does not play an oncogenic
role in neuroblastoma. Our report also complements with details
of the age distribution of the neuroblastoma patients (Table 3) and
that KI and WU polyomaviruses do not play an oncogenic role in
neuroblastoma either.
In conclusion, in this pilot study MCPyV, KI and WU have so
far not been shown to be causative of childhood CNS tumours or
neuroblastomas. However, additional data are warranted and we
do not exclude that other still not yet detected polyomaviruses
could be present in these tumour types.
Table 2. Relative frequencies of tumour biopsies in the main
diagnostic groups for CNS tumours as compared to their
frequencies in the whole of Sweden.
CNS tumours Diagnostic
groups*
Karolinska University
Hospital 2008–2009
VCTB
1984–2005**
Ependymoma 3 (12%) 10.5%
Astrocytoma 11
11 (44%) 44.6%
Medulloblastoma/PNET 5 (20%) 18.8%
Other Gliomas 2
12 (8%) 10%
Others specified neoplasms 3 (12%) 13.5%
Unspecified intracranial/
intraspinal neopl.
1
13 (4%) 2.5%
Total 25 (100%)
*according to the ‘‘classification scheme for childhood cancer’’ [47].
**from the Swedish Childhood CNS Tumour Working Group (VCTB) [44].
1Patients with tumours that can be due to inheritable diseases.
13/11 patients had Giant cell astrocytoma with Tuberous Sclerosis, and 1/4 had
Pilocytic astrocytoma with Neurofibromatosis type I.
21/2 patients had Leptomeningeal oligodendromatosis.
3this patient had Lumbar Schwannoma with Neurofibromatosis type II.
doi:10.1371/journal.pone.0008239.t002
Table 3. Overview of all tumours and results from the specific
PCRs testing.
Specimens Diagnosis/age KIPyV
1 WUPyV
1 MCPyV
1,2
31 Neuroblastomas 000
25 0–3 years old
3 4–6 years old
0 7–9 years old
3 9–11 years old
25 CNS tumours 000
1/1
2*
9 0–3 years old
10 4–6 years old
3 7–9 years old
1 9–11 years old
2 11–18 years old
1Tested by regular PCR, or
2 by quantitative real time PCR.
*Ct value 37.8 in ultrasound aspirate but negative in corresponding tumour
biopsy.
doi:10.1371/journal.pone.0008239.t003
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